Hypermarcas traded at 23.70 this Monday February 23rd, decreasing 0.13 or 0.55 percent since the previous trading session. Looking back, over the last four weeks, Hypermarcas lost 6.21 percent. Over the last 12 months, its price rose by 23.44 percent. Looking ahead, we forecast Hypermarcas to be priced at 23.22 by the end of this quarter and at 21.48 in one year, according to Trading Economics global macro models projections and analysts expectations.
Hypera SA, formerly Hypermarcas SA, is a Brazil-based company engaged in the pharmaceuticals sector. The Company’s major business units include Branded Prescription, Consumer Health and Branded Generics. Branded Prescription is present in the main therapeutic classes in Brazil and it operates in the Primary Care segment under the umbrella brand Mantecorp Farmasa. The Branded Prescription unit also acts as Mantecorp Skincare in dermocosmetics, with products recommended by dermatologists. Consumer Health offers non-prescription drugs, with brands such as Apracur, Benegrip, Coristina d, Engov, Epocler and Estomazil, among others. The Consumer Health unit also operates in nutritionals and vitamin supplements, with brands such as Tamarine, Vitasay, Biotonico Fontoura and Zero-Cal. Branded Generics operates under the Neo Quimica brand.